Dr Reddy's Laboratories has launched Montelukast Sodium Tablets (10 mg) and Montelukast Sodium Chewable Tablets (4 mg & 5 mg), bioequivalent generic versions of SINGULAIR tablets and Chewable tablets, in the US market on August 06, 2012 following the approval by the United States Food & Drug Administration (USFDA) of company's ANDA .
The company's Montelukast Sodium Tablets in 10 mg and Montelukast Sodium Chewable Tablets in 4 mg and 5 mg are available in bottle counts of 30 and 90. The SINGULAIR tablets and Chewable tablets brand had US sales of approximately $3.6 billion and $1.14 billion, respectively for the most recent twelve months ending March 2012 according to IMS Health.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.